Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales
Biogen’s Byooviz Biosimilar Launched 1 July; Company Stressed Gradual Launch
Executive Summary
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.
You may also be interested in...
Samsung Bioepis Launches Ranibizumab In Korea
Samsung Bioepis has announced the launch of its SB11 ranibizumab biosimilar rival to Lucentis in Korea through partner Samil. The introduction – under the name Amelivu – comes after the product was launched as Byooviz in the US last year.
Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar
Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.
US Tocilizumab Race Heats Up As Biogen Matches Kabi’s Filing
In a small pool of developers, Biogen has matched Fresenius Kabi by filing its proposed tocilizumab biosimilar with the US Food and Drug Administration.